Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Liver Cancer treatment details. Biologic therapy. Massachusetts General Hospital, Boston, MA, United States

Survival: 9.8 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: United States
City/State/Province: Boston, MA
Hospital: Massachusetts General Hospital
Journal: Link
Date: 6/2009

This phase II study involved 34 advanced hepatocellular carcinoma patients with a median age of 64 years; 85% were male.

Patients were treated with the biologic therapy agent sunitinib, which is a tyrosine kinase inhibitor that interferes with cancer cell growth.

There were 2 deaths reported during the early phase of treatment that were reported to be likely related to progression of their cancer. There were also 2 cases of grade 4 thrombocytopenia and 1 case of grade 4 pulmonary embolism. Grade 3 fatigue and anemia were also reported.

The median progression-free survival was 3.9 months and median overall survival was 9.8 months.

This study was partially funded by Pfizer, makers of Sutent (brand name for sunitinib).

Correspondence: Dr. Andrew X. Zhu; email:

E-mail to a Friend Email Physician More Information